• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

[In the News] Extended tamoxifen regimen reduces mortality for subset of breast cancer

bys25qthea
December 12, 2012
in Chronic Disease, Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

Key study points:

  1. Adjuvant tamoxifen for 10 years after diagnosis of early ER-positive breast cancer reduces recurrence and mortality compared to adjuvant tamoxifen for only 5 years.
  2. The main side effects were an increased risk of pulmonary embolism and endometrial cancer.

Primer: Breast cancers commonly express the estrogen receptor, and signaling through this receptor promotes tumor growth. Tamoxifen is a selective estrogen receptor modulator that inhibits estrogen signaling to tumor cells and can thereby inhibit tumor growth.

Tamoxifen is frequently given to premenopausal women, whereas postemenopausal women may receive aromatase inhibitors instead. Aromatase inhibitors block the production of estrogen in the body. This strategy is ineffective in premenopausal women because the reduction in estrogen levels stimulates gonadotropin secretion, which promotes estrogen synthesis and counteracts the effect of the aromatase inhibitor.

Adjuvant tamoxifen refers to the administration of tamoxifen after surgical removal of the primary tumor. Randomized trials have shown that adjuvant tamoxifen for 5 years is more effective than just 2 years. However, it is unclear whether adjuvant tamoxifen for more than 5 years provides additional benefit. The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial compares relapse and mortality in women who received adjuvant tamoxifen for either 5 or 10 years.

Background reading:

1. Coverage in the New York Times

RELATED REPORTS

Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe

2 Minute Medicine Rewind July 4, 2022

Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]

This [randomized controlled] study: The ATLAS trial enrolled 12,894 women from over 30 countries with early breast cancer and who had already been taking tamoxifen for approximately 5 years. Half the women were randomized to stop tamoxifen (control group) and the other half were randomized to continue for another 5 years (treatment group). All women were followed for 10 years from trial entry.

Only those with known ER-positive disease (6846 women) were used to evaluate the main outcomes (mortality and recurrence). Continued tamoxifen reduced the risk of recurrence in the trial period from 25.1% to 21.4% (RR 0.84, 95% CI 0.76 – 0.94; p=0.002). Overall mortality was also reduced in the treatment group (639 deaths in 3428 women vs. 722 deaths in 3418 women, p=0.01)

Notable side effects were an increased risk of pulmonary embolism and endometrial cancer. On the other hand, a reduction in ischemic heart disease was observed in the treatment group.

In sum: Longer adjuvant tamoxifen treatment reduces recurrence and mortality in women diagnosed with early ER-positive breast cancers. Tamoxifen appears to confer some carryover benefit, as the greatest differences in recurrence and mortality between the two groups were observed in the 5 years after the treatment group had stopped taking tamoxifen.

The consensus appears to be that the benefits of extended tamoxifen found in this study outweigh the risks and monetary cost (see Background Reading and Editorial in The Lancet).

Future studies are likely to explore even longer regimens of tamoxifen.

Click to read the study in The Lancet

Click to read an accompanying editorial in The Lancet

By [TJ] and [MP]

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Previous Post

The NINDS trial: Tissue plasminogen activator in acute ischemic stroke significantly improves functional outcomes [Classics Series]

Next Post

Novel antiviral drug reduces influenza viral load

RelatedReports

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Cardiology

Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe

July 4, 2022
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Weekly Rewinds

2 Minute Medicine Rewind July 4, 2022

July 4, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]

July 2, 2022
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers

July 1, 2022
Next Post

Novel antiviral drug reduces influenza viral load

Bronchial foreign bodies more common than tracheal foreign bodies in a pediatric population

Classics Series, Landmark Trials in Medicine

The RALES trial: Spironolactone decreases all-cause mortality in heart failure patients [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe
  • 2 Minute Medicine Rewind July 4, 2022
  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.